Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
31 hedge funds and large institutions have $108M invested in Genocea Biosciences, Inc. in 2014 Q1 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.6M |
| 2 |
DM
Deerfield Management
New York
|
+$10.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.65M |
| 4 |
Jennison Associates
New York
|
+$3.06M |
| 5 |
Axa
Paris,
France
|
+$2.55M |
Top Sellers
GNCA Hedge Fund Activity: Q1 2014 in Review
31 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2014, worth a combined $108M.
Buyers outnumbered sellers: 31 funds opened new GNCA positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $25.6M.
- 31 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $108M of Genocea Biosciences, Inc. stock for Q1 2014.
- 31 funds opened new Genocea Biosciences, Inc. positions in Q1 2014 and 0 closed out, a net change of +31 holders.
- The largest Genocea Biosciences, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $25.6M added.
Based on aggregated 13F filings for Q1 2014.